FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1645-1651 November 25, 1999 Number 22 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Large outbreaks of diarrhea caused by a newly recognized strain of Clostridium difficile occurred in four hospitals located in different parts of the United States between 1989 and 1992. Since frequent use of clindamycin was associated with the outbreak in one of the hospitals, we examined the resistance genes of the epidemic-strain isolates and studied the role of clindamycin use in these outbreaks.

Methods Case–control studies were performed at three of the four hospitals to assess the relation of the use of clindamycin to C. difficile–associated diarrhea. All isolates of the epidemic strain and representative isolates of other strains identified during each outbreak were tested for susceptibility to clindamycin. Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance — the erythromycin ribosomal methylase B (ermB ) gene — found in C. perfringens and C. difficile.

Results In a stratified analysis of the case–control studies with pooling of the results according to the Mantel–Haenszel method, we found that the use of clindamycin was significantly increased among patients with diarrhea due to the epidemic strain of C. difficile, as compared with patients whose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval, 2.02 to 9.38; P<0.001). Exposure to other types of antibiotics or hospitalization in a surgical ward was not significantly associated with the risk of C. difficile–associated diarrhea due to the epidemic strain. All epidemic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 µg per milliliter). DNA hybridization and PCR analysis showed that all these isolates had an ermB gene, which encodes a 23S ribosomal RNA methylase that mediates resistance to macrolide, lincosamide, and streptogramin antibiotics. Only 15 percent of the nonepidemic strains were resistant to clindamycin.

Conclusions A strain of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarrhea in four hospitals in different states. The use of clindamycin is a specific risk factor for diarrhea due to this strain. Resistance to clindamycin further increases the risk of C. difficile–associated diarrhea, an established complication of antimicrobial use.

Source Information

From the Infectious Disease Section, Department of Medicine, Veterans Affairs Chicago Health Care System, Lakeside Division, and Northwestern University Medical School, Chicago (S.J., D.N.G.); the Infectious Disease Section, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (M.H.S., P.D.); the Department of Microbiology, Monash University, Clayton, Victoria, Australia (K.A.F., D.L., J.I.R.); the Centers for Disease Control and Prevention, Atlanta (G.E.K., F.C.T.); the Stratton Veterans Affairs Medical Center and Albany Medical College, Albany, N.Y. (A.L.B., M.E.R.); and the Veterans Affairs Medical Center, Tucson, Ariz. (S.M.P.).

Address reprint requests to Dr. Johnson at the Veterans Affairs Chicago Health Care System, Lakeside Division, Medicine Service, 333 East Huron, Chicago, IL 60611, or at stu-johnson{at}nwu.edu.

Full Text of this Article

This article has been cited by other articles:

• Deneve, C., Bouttier, S., Dupuy, B., Barbut, F., Collignon, A., Janoir, C. (2009). Effects of Subinhibitory Concentrations of Antibiotics on Colonization Factor Expression by Moxifloxacin-Susceptible and Moxifloxacin-Resistant Clostridium difficile Strains. Antimicrob. Agents Chemother. 53: 5155-5162 [Abstract] [Full Text]  
• Limbago, B. M., Long, C. M., Thompson, A. D., Killgore, G. E., Hannett, G. E., Havill, N. L., Mickelson, S., Lathrop, S., Jones, T. F., Park, M. M., Harriman, K. H., Gould, L. H., McDonald, L. C., Angulo, F. J. (2009). Clostridium difficile Strains from Community-Associated Infections. J. Clin. Microbiol. 47: 3004-3007 [Abstract] [Full Text]  
• Williams, O. M., Spencer, R. C. (2009). The management of Clostridium difficile infection. Br Med Bull 91: 87-110 [Abstract] [Full Text]  
• Kelly, C. P. (2009). A 76-Year-Old Man With Recurrent Clostridium difficile-Associated Diarrhea: Review of C difficile Infection. JAMA 301: 954-962 [Abstract] [Full Text]  
• Akerlund, T., Persson, I., Unemo, M., Noren, T., Svenungsson, B., Wullt, M., Burman, L. G. (2008). Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1. J. Clin. Microbiol. 46: 1530-1533 [Abstract] [Full Text]  
• Hecht, D. W., Galang, M. A., Sambol, S. P., Osmolski, J. R., Johnson, S., Gerding, D. N. (2007). In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004. Antimicrob. Agents Chemother. 51: 2716-2719 [Abstract] [Full Text]  
• Adams, D. A., Riggs, M. M., Donskey, C. J. (2007). Effect of Fluoroquinolone Treatment on Growth of and Toxin Production by Epidemic and Nonepidemic Clostridium difficile Strains in the Cecal Contents of Mice. Antimicrob. Agents Chemother. 51: 2674-2678 [Abstract] [Full Text]  
• Jump, R. L. P., Pultz, M. J., Donskey, C. J. (2007). Vegetative Clostridium difficile Survives in Room Air on Moist Surfaces and in Gastric Contents with Reduced Acidity: a Potential Mechanism To Explain the Association between Proton Pump Inhibitors and C. difficile-Associated Diarrhea?. Antimicrob. Agents Chemother. 51: 2883-2887 [Abstract] [Full Text]  
• Freeman, J., Baines, S. D., Saxton, K., Wilcox, M. H. (2007). Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 60: 83-91 [Abstract] [Full Text]  
• Drudy, D., Quinn, T., O'Mahony, R., Kyne, L., O'Gaora, P., Fanning, S. (2006). High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58: 1264-1267 [Abstract] [Full Text]  
• Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
• Bartlett, J. G. (2006). Narrative Review: The New Epidemic of Clostridium difficile-Associated Enteric Disease.. ANN INTERN MED 145: 758-764 [Abstract] [Full Text]  
• Stabler, R. A., Gerding, D. N., Songer, J. G., Drudy, D., Brazier, J. S., Trinh, H. T., Witney, A. A., Hinds, J., Wren, B. W. (2006). Comparative Phylogenomics of Clostridium difficile Reveals Clade Specificity and Microevolution of Hypervirulent Strains.. J. Bacteriol. 188: 7297-7305 [Abstract] [Full Text]  
• Aspevall, O., Lundberg, A., Burman, L. G., Akerlund, T., Svenungsson, B. (2006). Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital.. Antimicrob. Agents Chemother. 50: 1890-1892 [Abstract] [Full Text]  
• Musher, D. M., Logan, N., Mehendiratta, V., Polk, R. E., Oinonen, M., Pakyz, A., Wilcox, M. H., Freeman, J., Iwata, K., Doi, A., Furuya, N., McDonald, L. C., Gerding, D. N., Loo, V. G., Libman, M. D., Dascal, A. (2006). Epidemic Clostridium difficile.. NEJM 354: 1199-1203 [Full Text]  
• Pituch, H., Brazier, J. S., Obuch-Woszczatynski, P., Wultanska, D., Meisel-Mikolajczyk, F., Luczak, M. (2006). Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J Med Microbiol 55: 207-213 [Abstract] [Full Text]  
• Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., Vibien, A., Brassard, P., Fenn, S., Dewar, K., Hudson, T. J., Horn, R., Rene, P., Monczak, Y., Dascal, A. (2005). A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile-Associated Diarrhea with High Morbidity and Mortality. NEJM 353: 2442-2449 [Abstract] [Full Text]  
• McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C. Jr., Kazakova, S. V., Sambol, S. P., Johnson, S., Gerding, D. N. (2005). An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile. NEJM 353: 2433-2441 [Abstract] [Full Text]  
• Spigaglia, P., Barbanti, F., Mastrantonio, P. (2005). Horizontal Transfer of Erythromycin Resistance from Clostridium difficile to Butyrivibrio fibrisolvens. Antimicrob. Agents Chemother. 49: 5142-5145 [Abstract] [Full Text]  
• Asha, N. J., Fawley, W. N., Freeman, J., Wilcox, M. H. (2005). Increased Rate of DNA Recovery from United Kingdom Epidemic Clostridium difficile PCR Ribotype 1 Strains Stored Cryogenically. J. Clin. Microbiol. 43: 5794-5795 [Abstract] [Full Text]  
• Louie, T. J. (2005). How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. CMAJ 173: 1049-1050 [Full Text]  
• Fawley, W. N., Parnell, P., Verity, P., Freeman, J., Wilcox, M. H. (2005). Molecular Epidemiology of Endemic Clostridium difficile Infection and the Significance of Subtypes of the United Kingdom Epidemic Strain (PCR Ribotype 1). J. Clin. Microbiol. 43: 2685-2696 [Abstract] [Full Text]  
• Kato, H., Yokoyama, T., Arakawa, Y. (2005). Typing by sequencing the slpA gene of Clostridium difficile strains causing multiple outbreaks in Japan. J Med Microbiol 54: 167-171 [Abstract] [Full Text]  
• Spigaglia, P., Mastrantonio, P. (2004). Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 53: 1129-1136 [Abstract] [Full Text]  
• Noren, T., Akerlund, T., Back, E., Sjoberg, L., Persson, I., Alriksson, I., Burman, L. G. (2004). Molecular Epidemiology of Hospital-Associated and Community-Acquired Clostridium difficile Infection in a Swedish County. J. Clin. Microbiol. 42: 3635-3643 [Abstract] [Full Text]  
• Louie, T. J., Meddings, J. (2004). Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 171: 45-46 [Full Text]  
• Svenungsson, B., Burman, L. G., Jalakas-Pornull, K., Lagergren, A., Struwe, J., Akerlund, T. (2003). Epidemiology and Molecular Characterization of Clostridium difficile Strains from Patients with Diarrhea: Low Disease Incidence and Evidence of Limited Cross-Infection in a Swedish Teaching Hospital. J. Clin. Microbiol. 41: 4031-4037 [Abstract] [Full Text]  
• Pituch, H., van Belkum, A., van den Braak, N., Obuch-Woszczatynski, P., Verbrugh, H., Meisel-Mikolajczyk, F., Luczak, M. (2003). Recent Emergence of an Epidemic Clindamycin-Resistant Clone of Clostridium difficile among Polish Patients with C. difficile-Associated Diarrhea. J. Clin. Microbiol. 41: 4184-4187 [Abstract] [Full Text]  
• Thomas, C., Stevenson, M., Riley, T. V. (2003). Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 51: 1339-1350 [Abstract] [Full Text]  
• Ackermann, G., Degner, A., Cohen, S. H., Silva, J. Jr, Rodloff, A. C. (2003). Prevalence and association of macrolide-lincosamide- streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51: 599-603 [Abstract] [Full Text]  
• Drummond, L. J., McCoubrey, J., Smith, D. G. E., Starr, J. M., Poxton, I. R. (2003). Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 52: 259-263 [Abstract] [Full Text]  
• Morris, A. M., Jobe, B. A., Stoney, M., Sheppard, B. C., Deveney, C. W., Deveney, K. E. (2002). Clostridium difficile Colitis: An Increasingly Aggressive Iatrogenic Disease?. Arch Surg 137: 1096-1100 [Abstract] [Full Text]  
• Bartlett, J. G. (2002). Antibiotic-Associated Diarrhea. NEJM 346: 334-339 [Full Text]  
• Eggimann, P., Pittet, D. (2001). Infection Control in the ICU. Chest 120: 2059-2093 [Abstract] [Full Text]  
• Farrow, K. A., Lyras, D., Rood, J. I. (2001). Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology 147: 2717-2728 [Abstract] [Full Text]  
• Kato, H., Kato, N., Watanabe, K., Yamamoto, T., Suzuki, K., Ishigo, S., Kunihiro, S., Nakamura, I., Killgore, G. E., Nakamura, S. (2001). Analysis of Clostridium difficile Isolates from Nosocomial Outbreaks at Three Hospitals in Diverse Areas of Japan. J. Clin. Microbiol. 39: 1391-1395 [Abstract] [Full Text]  
• Mylonakis, E., Ryan, E. T., Calderwood, S. B. (2001). Clostridium difficile-Associated Diarrhea: A Review. Arch Intern Med 161: 525-533 [Abstract] [Full Text]  
• Freeman, J., Wilcox, M. H. (2001). Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 47: 244-246 [Full Text]  
• Wilcox, M. H., Fawley, W., Freeman, J., Brayson, J. (2000). In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 46: 551-556 [Abstract] [Full Text]  
• Gorbach, S. L. (1999). Antibiotics and Clostridium difficile. NEJM 341: 1689-1691 [Full Text]